TQB3909 + TQB3702

TQB3909 + TQB3702 is an investigational **oral combination therapy** under development for the treatment of hematologic malignancies, including specific types of non-Hodgkin’s lymphoma. TQB3909 is a **selective small-molecule inhibitor of B-cell lymphoma 2 (BCL-2)**, a protein that prevents apoptosis in malignant cells. By inhibiting BCL-2, TQB3909 promotes apoptosis (programmed cell death) in cancer cells. TQB3702’s mechanism of action is not specified in available sources, but it is being clinically evaluated together with TQB3909 for synergistic effects in blood cancers. Both agents are orally administered and under evaluation in multi-phase clinical trials for safety, tolerability, and preliminary efficacy in patients with hematologic malignancies. The primary developer for both drugs is Chia Tai Tianqing Pharmaceutical Group.